Scalper1 News
Regenxbio (RGNX) turned in a strong performance Wednesday, with an upsized initial public offering that raised $138.6 million. The biotech company priced 6.3 million shares, above previous plans to offer 5.6 million shares, at 22 a share. Its initial expected price range was 17 to 19. Research firm IPOboutique.com previously reported that the deal was “multiple times oversubscribed.” Regenexbio is focused on developing, commercializing and Scalper1 News
Scalper1 News